Analyst Ratings for Karyopharm Therapeutics (KPTI)
KPTI Rating Summary
KPTI Price Target Summary
- Highest: $28.00 (Rodman & Renshaw)
- Lowest: $5.00 (Leerink)
- Average: $14.14
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
=
Avg. $ Target:
$14.14 (+56.8%)
* Over Last 12-Mos
Rating Score: 7.2 / 10
Percentile Rank: 76%
Rating Score: 7.2 / 10
Percentile Rank: 76%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/9/2026 | Rodman & Renshaw | Michael King Jr. | New Coverage | Buy (N/A) |
28.00 (N/A) |
8.77 (9.02) |
2.85% | Details |
| 2/5/2026 | Cantor Fitzgerald » Updated 6/9/2026 |
Yanni Souroutzidis | New Coverage | Overweight (N/A) |
N/A (N/A) |
6.55 (9.02) |
37.71% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
